Abstract
Studies reported by CCSG (Miller et al. 1974; Robison et al. 1980), other cooperative groups (George et al. 1973), and independent pediatric cancer centers (Simone 1976) have clearly indicated that front-end prognostic factors can be as important, or more important, than the therapy itself in determining the results of a modern clinical trial in previously untreated children with acute lymphoblastic leukemia (ALL). This effect becomes even more pronounced as the majority of patients are surviving free of disease for 5 or more years. Definitive results of clinical trials may require 5 to 7 years of follow up to determine the optimal duration of therapy or even longer to determine the rate of long-term survival.
Principal investigators of CCSG and their grant support are listed in the acknowledgments
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Andreeff M, Darzynkiewicz Z, Sharpless TK, Clarkson BD, Melamed MR (1980) Discrimination of heman leukemia subtypes by flow cytometric analysis of cellular DNA and RNA. Blood 55:282–293
Aur RJA, Simone JV, Verzoza MS, Hustu HD, Barker LF, Pinkel DP, Rivera G, Dahl GV, Wood A, Stagner S, Mason C (1978) Childhood acute lymphocytic leukemia. Study VIII. Cancer 42:2123–2134
Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DAG, Gralnick NR, Sultan D (French-American-British [FAB] Cooperative Group) (1976) Proposal for the classification of the acute leukemias. Br J Haematol 33:451–458
Cox DR Regression models and liefe tables. J R Stat Soc [Br] 34:187–220
Fahey J, McKelvey EM (1965) Quantitative determination of serum Immunoglobulins in antibody agar plates. J Immunol 94:84–90
Frei EJ, Sallan SE (1978) Acute lymphoblastic leukemia treatment. Cancer 42:828–838
George S, Fernbach K, Vietti T, Sullivan MP, Lane DM, Haggard ME, Berry DH, Lonsdale D, Komp D (1973) Factors influencing survival in pediatric acute leukemia. Cancer 32:1542–1553
Haghbin M, Tan CT, Clarkson BD, Mike V, Burchenal J, Murphy ML (1974) Intensive chemotherapy in children with acute lymphoblastic leukemia (L-2 protocol). Cancer 33:1491–1498
Haghbin M, Murphy ML, Tan CTC, Clarkson BD, Thaler H, Passe S, Burchenal J (1981) A long-term clinical follow-up of children with acute lymphoblastic leukemia treated with intensive chemotherapy regimens. Cancer 46:241–252
Jacquillat C, Weil M, German MF (1974) Combination therapy in 130 patients with acute lymphocytic leukemia. Cancer Res 33:3284–3289
Leikin S, Miller DR, Sather H, Albo V, Esber E, Johnson A, Rogentine N, Hammond D (to be published) Immunologic evaluation in the prognosis of acute lymphoblastic leukemia. Blood
Miller DR, Sonley M, Karon M, Breslow N, Hammond D (1974) Additive therapy in the maintenance of remission in acute lymphoblastic leukemia of childhood: the effect of the initial leukocyte count. Cancer 34:508–517
Miller DR, Leikin S, Albo V, Sather H, Hammond D (to be published) Prognostic significance of lymphoblast morphology (FAB classification) in childhood acute lymphoblastic leukemia. Br J Haematol
Nesbit ME, Coccia PF, Sather HN, Robison LL, Hammond GD (1979) Staging in pediatrie malignancies. In: Proceedings of american cancer society national conference on the care of the child with cancer. American Cancer Society, New York, pp 31–38
Peto R, Pike MC, Armitage P, Breslow NE, Cox DR, Howard SV, Mantel N, McPherson K, Peto J, Smith PG (1977) Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examples. Br J Cancer 35:1–39
Robison LL, Sather HN, Coccia PF, Nesbit ME, Hammond GD (1980) Assessment of the interrelationship of prognostic factors in childhood acute lymphoblastic leukemia: A report from Childrens Cancer Study Group. Am J Pediatr Hematol Oncol 2:5–14
Sallan SE, Ritz J, Pesando J, Geiber R, O’Brien C, Hitchcock S, Coral F, Schlossman SF (1980) Cell surface antigens: Prognostic implications in childhood acute lymphoblastic leukemia. Blood 55: 395–402
Simone JV, Aur RJA, Hustu HO, Verzosa M, Pinkel D (1975) Combined modality therapy of acute lymphocytic leukemia. Cancer 35:25–35
Simone JV (1976) Factors that influence haematological remission duration in acute lymphocytic leukaemia. Br J Haematol 32:465–472
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1981 Springer-Verlag Berlin Heidelberg
About this paper
Cite this paper
Miller, D.R., Leikin, S., Albo, V., Sather, H., Karon, M., Hammond, D. (1981). Intensive Therapy and Prognostic Factors in Acute Lymphoblastic Leukemia of Childhood: CCG 141. In: Neth, R., Gallo, R.C., Graf, T., Mannweiler, K., Winkler, K. (eds) Modern Trends in Human Leukemia IV. Haematology and Blood Transfusion / Hämatologie und Bluttransfusion, vol 26. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-67984-1_12
Download citation
DOI: https://doi.org/10.1007/978-3-642-67984-1_12
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-10622-7
Online ISBN: 978-3-642-67984-1
eBook Packages: Springer Book Archive